CAR T-Cell Therapy

There remains a significant unmet need for better treatments that prolong life and preserve the quality of life in women with metastatic breast cancer.

The allogeneic CAR T-cell therapy CT0596 was safe with clinical activity in relapsed/refractory multiple myeloma.

The top 5 OncLive videos of the week cover insights in chronic lymphocytic leukemia, ovarian cancer, multiple myeloma, and large B-cell lymphoma.

A multicenter review comparing ide-cel and cilta-cel in relapsed/refractory multiple myeloma showed better survival with cilta-cel but increased toxicity.

Sairah Ahmed, MD, discusses safety data with NKTR-255 in patients with relapsed/refractory large B-cell lymphoma.

Inati-cel generated complete remissions and MRD negativity in CD19-positive relapsed/refractory B-cell acute lymphoblastic leukemia.

Alfred L. Garfall, MD, MS, discusses the rationale of the phase 2 BMT CTN 1902 trial in multiple myeloma.

Andrew Ip, MD, discusses the need for real-world studies investigating the efficacy and safety of CAR T-cell therapy in patients with LBCL.

Michael R. Bishop, MD, explains the rationale for assessing the CAR T-cell therapy anito-cel in relapsed/refractory multiple myeloma.

Yeong “Christopher” Choi, PhD, MBA, discusses importance of product and process education to mitigate variability in CAR T-cell therapy manufacturing in hematologic malignancies.

The top 5 OncLive videos of the week cover insights in multiple myeloma, AL amyloidosis, myelofibrosis, breast cancer, and sarcoma.

María-Victoria Mateos, MD, PhD, discusses data from the long-term update of CARTITUDE-4 she presented during the 51st Annual EBMT Meeting.

On-site adaptive manufacturing of LV20.19 resulted in a high complete response rate and favorable tolerability in relapsed/refractory mantle cell lymphoma.

Dasatinib plus CAR T cells led to high CMR and LFS rates with a good safety profile in Ph-positive acute lymphoblastic leukemia.

Kiavasch Mohammad Nejad Farid, MD, discusses the signs of activity and safety with MDC-CAR-BCMA001 in pretreated patients with AL amyloidosis and myeloma.

Kiavasch Mohammad Nejad Farid, MD, discusses how compassionate use of MDC-CAR-BCMA001 could address unmet needs for multiple myeloma and AL amyloidosis.

Yeong “Christopher” Choi, PhD, MBA, discusses the importance of developing biomedical technologies for hematologic malignancies and other diseases.

Treatment with cilta-cel led to improvements across several QOL subscales compared with SOC therapy in patients with lenalidomide-refractory myeloma.

Early infection risk following cilta-cel infusion in patients with multiple myeloma emphasizes the importance of monitoring for treatment-emergent infections.

As we plan for a future with solid tumor CAR T-cell therapy, we should be mindful of lessons learned from CAR T-cell agents for hematologic malignancies.

Nirav Shah, MD, discusses the clinical implications and future directions for zamto-cel in patients with relapsed/refractory diffuse large B-cell lymphoma.

Alfred L. Garfall, MD, discusses the role of ide-cel in patients with multiple myeloma following suboptimal responses to upfront auto-HCT.

The top 5 OncLive videos of the week cover insights in multiple myeloma, AL amyloidosis, ovarian cancer, prostate cancer, breast cancer, and follicular lymphoma.

Orca-T boosts cGVHD-free survival in hematologic malignancies, cilta-cel continues to impress in CARTITUDE-4, and more.

A small sample size from an analysis of the FELIX trial suggests consolidative SCT may not be needed after obe-cel treatment in relapsed/refractory B-ALL.